Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

September 30, 2003

Study Completion Date

May 31, 2005

Conditions
Abdominal ObesityMetabolic SyndromeObesity
Interventions
DRUG

recombinant human growth hormone

The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects

Trial Locations (1)

413 45

Centrum for Endocrinology and Metabolism, Sahlgenska University Hospital, Gothenburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Göteborg University

OTHER